Luseogliflozin hydrate

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1152425-66-5

TS 071 hydrate

Luseogliflozin (TS 071) hydrate 是一种选择有效的,具有口服活性的第二代钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂，IC₅₀为 2.26 nM。Luseogliflozin hydrate 可用于 2 型糖尿病的研究。

生物活性

Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM)^[1]^[2].

IC₅₀& Target

SGLT2

体外研究
(In Vitro)

Luseogliflozin can increase beta cell proliferation through the activation of the FoxM1/PLK1/CENP-A pathway via humoral factors thats act in an insulin/IGF-1 receptor-independent manner. Luseogliflozin increases beta cell proliferation in OSI-906-treated mice^[2].

Cell Viability Assay^[2]

Cell Line:	βIRKO, IRS1KO and IRS2KO beta cells
Concentration:	100 nM
Incubation Time:	24 and 48 hours
Result:	Cell Viability Assay^[2]Treating cells with serum from the OSI-906 (200 nM) or OSI-906+Luseogliflozin(100 nM) group led to significantly increased cell viability in the latter group in the control, IRS1KO, IRS2KO, as well as the insulin receptor (IR)-deficient βIRKO beta cells.

体内研究
(In Vivo)

SGLT2 inhibition with Luseogliflozin (10 mg/kg/daily; oral gavage) significantly ameliorates hyperglycaemia, but not hyperinsulinaemia, in the OSI-906(45 mg/kg)-treated mice. Luseogliflozin ameliorates hyperglycaemia induced by OSI-906^[2].

Animal Model:	C57BL/6J male mice aged 8 weeks old^[2]
Dosage:	10 mg/kg/daily
Administration:	Oral gavage; for 7 days between 08:00 and 09:00 hours
Result:	Treatment significantly ameliorated the OSI-906 (45 mg/kg)-induced hyperglycaemia.

Clinical Trial

分子量

452.56

Formula

C₂₃H₃₂O₇S

CAS 号

1152425-66-5

中文名称

鲁格列净水合物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.